0V0 logo

Vimian Group DB:0V0 Stock Report

Last Price

€3.22

Market Cap

€1.8b

7D

-4.8%

1Y

25.0%

Updated

23 Apr, 2025

Data

Company Financials +

0V0 Stock Overview

Engages in the animal health business worldwide. More details

0V0 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance5/6
Financial Health3/6
Dividends0/6

Community vs My Fair Value

Select a narrative for quick price alerts from the community, or create your own.

Vimian Group AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Vimian Group
Historical stock prices
Current Share PriceSEK 3.22
52 Week HighSEK 4.16
52 Week LowSEK 2.43
Beta1.57
1 Month Change-10.80%
3 Month Change-6.40%
1 Year Change25.05%
3 Year Change-42.65%
5 Year Changen/a
Change since IPO-64.02%

Recent News & Updates

Recent updates

Shareholder Returns

0V0DE Medical EquipmentDE Market
7D-4.8%0.1%0.4%
1Y25.0%-16.7%6.5%

Return vs Industry: 0V0 exceeded the German Medical Equipment industry which returned -16.7% over the past year.

Return vs Market: 0V0 exceeded the German Market which returned 6.5% over the past year.

Price Volatility

Is 0V0's price volatile compared to industry and market?
0V0 volatility
0V0 Average Weekly Movement8.7%
Medical Equipment Industry Average Movement5.7%
Market Average Movement6.2%
10% most volatile stocks in DE Market12.6%
10% least volatile stocks in DE Market3.1%

Stable Share Price: 0V0 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 0V0's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20201,200Patrik Erikssonvimian.com

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.

Vimian Group AB (publ) Fundamentals Summary

How do Vimian Group's earnings and revenue compare to its market cap?
0V0 fundamental statistics
Market cap€1.79b
Earnings (TTM)€18.50m
Revenue (TTM)€374.80m

96.6x

P/E Ratio

4.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0V0 income statement (TTM)
Revenue€374.80m
Cost of Revenue€116.50m
Gross Profit€258.30m
Other Expenses€239.80m
Earnings€18.50m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Apr 29, 2025

Earnings per share (EPS)0.035
Gross Margin68.92%
Net Profit Margin4.94%
Debt/Equity Ratio30.6%

How did 0V0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/23 03:32
End of Day Share Price 2025/04/23 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vimian Group AB (publ) is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Hassan Al-WakeelBarclays
Blanka PorkolabBarclays